{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:42:02Z","timestamp":1790743322567,"version":"4.1.0"},"reference-count":16,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2013,3,25]],"date-time":"2013-03-25T00:00:00Z","timestamp":1364169600000},"content-version":"vor","delay-in-days":2824,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2005,7]]},"abstract":"<jats:p>The influence of renal impairment on the pharmacokinetics of eplerenone following single and multiple dosing was evaluated. Subjects (n = 64) were stratified based on creatinine clearance values as follows: renal impairment (mild, moderate, severe), hemodialysis, and normal matches. Subjects received a single dose of eplerenone 100 mg on day 1 and then received 100 mg once daily on days 3 to 8. There were no statistically significant differences between any of the renal impairment groups and their matched\u2010normal groups for area under the curve (AUC), C<jats:sub>max<\/jats:sub>, or CL\/F or CL\/F\/WT following either single or multiple dosing (P \u2265 .093). The inactive metabolite and inactive ring\u2010opened form displayed greater AUCs in renal impairment. Hemodialysis removed approximately 10% of the eplerenone dose. Eplerenone 100 mg once daily was well tolerated in all groups. Considering that renal function had no significant effects on eplerenone CL\/F and that eplerenone metabolites are inactive, no dose adjustment appears necessary in patients with renal dysfunction.<\/jats:p>","DOI":"10.1177\/0091270005275894","type":"journal-article","created":{"date-parts":[[2005,6,10]],"date-time":"2005-06-10T18:13:38Z","timestamp":1118427218000},"page":"810-821","source":"Crossref","is-referenced-by-count":39,"title":["Pharmacokinetics of Eplerenone After Single and Multiple Dosing in Subjects With and Without Renal Impairment"],"prefix":"10.1002","volume":"45","author":[{"given":"William R.","family":"Ravis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenic A.","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwain S.","family":"Tolbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,25]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"650","article-title":"Three new epoxy\u2010spironolactone derivatives: characterization in vivo and in vitro","volume":"240","author":"Gasparo M","year":"1987","journal-title":"J Pharmacol Exp Ther."},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.2001.tb00064.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4892(01)00022-4"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2002.tb04415.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(97)00091-6"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(97)00097-7"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1071-9164(96)80009-1"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.0910457"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000025146.19104.FE"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.129970"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2002.01510.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(02)00964-9"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(02)00595-2"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00056-0"},{"key":"e_1_2_5_17_2","first-page":"1317","article-title":"Decreased in vivo metabolism of drugs in chronic renal failure","volume":"28","author":"Leblond FA","year":"2000","journal-title":"Drug Metab Dispos."}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270005275894","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270005275894","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:20:32Z","timestamp":1697156432000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270005275894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.1177\/0091270005275894"],"URL":"https:\/\/doi.org\/10.1177\/0091270005275894","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}